

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/00, 47/40</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/31178</b> <b>(43) International Publication Date:</b> 23 November 1995 (23.11.95)
<p><b>(21) International Application Number:</b> PCT/EP95/01760</p> <p><b>(22) International Filing Date:</b> 10 May 1995 (10.05.95)</p> <p><b>(30) Priority Data:</b>            94201402.8                      18 May 1994 (18.05.94)                      EP  <b>(34) Countries for which the regional or international application was filed:</b> DE et al.</p> <p><b>(71) Applicant (for all designated States except US):</b> JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).</p> <p><b>(72) Inventors; and</b>  <b>(75) Inventors/Applicants (for US only):</b> PUTTEMAN, Peter [BE/BE]; Wettersestraat 2A, B-9260 Schellebelle (BE). FRANÇOIS, Marc, Karel, Jozef [BE/BE]; Foxemaatstraat 64, B-2920 Kalmthout (BE). SNOECKX, Eric, Carolus, Leonarda [BE/BE]; Peerdekensstraat 23, B-2340 Beerse (BE).</p>		<p><b>(81) Designated States:</b> AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</p> <p><b>Published</b>  <i>-With international search report.            Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p><b>(54) Title:</b> MUCOADHESIVE EMULSIONS CONTAINING CYCLODEXTRIN</p> <p><b>(57) Abstract</b></p> <p>The present invention relates to the use of a cyclodextrin or a derivative thereof as a mucoadhesive in an emulsion or aqueous solution, said cyclodextrin or derivative thereof being used in an amount from 10 % to 70 % by weight based on the total weight of the composition.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## Mucoadhesive emulsions containing cyclodextrin

5

The development of an efficacious and readily manageable composition for vaginal use requires a satisfactory adhesion of the composition to the mucous membranes of the vagina in order to prevent the excretion of the product. A vaginal composition, therefore, should preferably show adequate mucoadhesive properties.

The gels, foams, creams, suppositories and tablets that are presently used in the treatment of vaginal afflictions break down very rapidly after insertion into the vaginal cavity and have insufficient bioadherence to the vaginal walls. Hence, an unpleasant leakage is often experienced after administration and the effectivity of these products is limited. The present invention solves the problem by furnishing a mucoadhesive emulsion which comprises between 10% and 70% by weight of a cyclodextrin.

In particular, the present invention is concerned with the use of a cyclodextrin or a derivative thereof as a mucoadhesive in an emulsion or aqueous solution, said cyclodextrin or derivative thereof being used in an amount from 10% to 70% by weight based on the total weight of the composition. The subject mucoadhesive compositions may be applied to the mucous membranes of, for example, the nose, mouth and in particular of the vagina. Preferably, the composition comprises a drug such as, for example, an antibacterial, an antiviral, an anticonceptive or, in particular, an antifungal. Antifungals that may be included in the subject compositions are, for example, miconazole, clotrimazole, ketoconazole, terconazole, econazole, butoconazole, fluconazole, and, preferably, itraconazole.

A further aspect of the invention relates to mucoadhesive emulsions comprising itraconazole and a cyclodextrin or a derivative thereof in an amount between 10% and 70% by weight based on the total weight of the composition. Optionally, the subject compositions may comprise, apart from the cyclodextrin, further constituents having mucoadhesive properties.

35

Itraconazole is a broadspectrum antifungal compound and is disclosed in US-4,267,179.

In addition to their favourable mucoadhesive properties, the itraconazole compositions of the present invention show a further advantage in that cure rates in vaginal afflictions are higher and relapse rates are lower when compared to commercially available, antifungal compositions. Moreover, the present itraconazole compositions have an excellent  
5 physicochemical stability.

Itraconazole is the generic name of 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one. The term "itraconazole" as used  
10 herein comprises the free base form, the pharmaceutically acceptable addition salts, the stereochemically isomeric forms thereof and the tautomeric forms thereof. The preferred itraconazole compound is the ( $\pm$ )-(cis) form of the free base form.

The acid addition forms may be obtained by reaction of the base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids such as, for example, acetic, propanoic, hydroxyacetic,  
15 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-butenedioic, (E)-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzene-  
20 sulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. The term addition salt as used hereinabove also comprises the solvates. Said solvates are meant to be included within the scope of the present invention. Examples of such solvates are, e.g. the hydrates, alcoholates and the like.

25 The formation of an addition salt of the drug may be adopted to increase the solubility thereof in the aqueous phase.

The present compositions comprise a cyclodextrin or a derivative thereof. Appropriate cyclodextrin derivatives are  $\alpha$ -,  $\beta$ -,  $\gamma$ -cyclodextrins or ethers and mixed  
30 ethers thereof wherein one or more of the hydroxy groups of the anhydroglucose units of the cyclodextrin are substituted with C<sub>1-6</sub>alkyl, particularly methyl, ethyl or isopropyl; hydroxyC<sub>1-6</sub>alkyl, particularly hydroxyethyl, hydroxypropyl or hydroxybutyl; carboxyC<sub>1-6</sub>alkyl, particularly carboxymethyl or carboxyethyl; C<sub>1-6</sub>alkyl-carbonyl, particularly acetyl; C<sub>1-6</sub>alkyloxycarbonylC<sub>1-6</sub>alkyl or carboxyC<sub>1-6</sub>alkyl-oxyC<sub>1-6</sub>alkyl,  
35 particularly carboxymethoxypropyl or carboxyethoxypropyl; C<sub>1-6</sub>alkylcarbonyloxy-C<sub>1-6</sub>alkyl, particularly 2-acetyloxypropyl. Especially noteworthy as complexants and/or solubilizers are  $\beta$ -CD, 2,6-dimethyl- $\beta$ -CD, 2-hydroxyethyl- $\beta$ -CD, 2-hydroxyethyl- $\gamma$ -CD,

2-hydroxypropyl- $\gamma$ -CD and (2-carboxymethoxy)propyl- $\beta$ -CD, and in particular 2-hydroxypropyl- $\beta$ -CD.

The term mixed ether denotes cyclodextrin derivatives wherein at least two cyclodextrin hydroxy groups are etherified with different groups such as, for example,

5 hydroxypropyl and hydroxyethyl.

The average molar substitution (M.S.) is used as a measure of the average number of moles of alkoxy units per mole of anhydroglucose. The M.S. value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative. In the cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention the M.S. as determined by mass spectrometry is in the range of 0.125 to 10, in particular of 0.3 to 3, or from 0.3 to 1.5. Preferably the M.S. ranges from about 0.3 to about 0.8, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. M.S. values determined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.

The average substitution degree (D.S.) refers to the average number of substituted hydroxyls per anhydroglucose unit. The D.S. value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative. In the cyclodextrin derivatives for use in the compositions according to the present invention the D.S. as determined by MS is in the range of 0.125 to 3, in particular of 0.2 to 2 or from 0.2 to 1.5. Preferably the D.S. ranges from about 0.2 to about 0.7, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. D.S. values determined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.

Preferably the amount of unsubstituted  $\beta$ - or  $\gamma$ -cyclodextrin is less than 5% of the total cyclodextrin content and in particular is less than 1.5%. Particularly interesting cyclodextrin derivative is randomly methylated  $\beta$ -cyclodextrin. More particular  $\beta$ - and  $\gamma$ -cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention are partially substituted cyclodextrin derivatives wherein the average degree of alkylation at hydroxyl groups of different positions of the anhydroglucose units is about 0% to 20% for the 3 position, 2% to 70% for the 2 position and about 5% to 90% for the 6 position.

Most preferred cyclodextrin derivatives for use in the present invention are those partially substituted  $\beta$ -cyclodextrin ethers or mixed ethers having hydroxypropyl, hydroxyethyl and in particular 2-hydroxypropyl and/or 2-(1-hydroxypropyl) substituents.

5 The most preferred cyclodextrin derivative for use in the compositions of the present invention is hydroxypropyl- $\beta$ -cyclodextrin having a M.S. in the range of from 0.35 to 0.50 and containing less than 1.5% unsubstituted  $\beta$ -cyclodextrin. M.S. values determined by NMR or IR preferably range from 0.55 to 0.75.

10 Substituted cyclodextrins can be prepared according to procedures described in US-3,459,731, EP-A-0,149,197, EP-A-0,197,571, US-4,535,152, WO-90/12035 and GB-2,189,245. Other references describing cyclodextrins for use in the compositions according to the present invention, and which provide a guide for the preparation, purification and analysis of cyclodextrins include the following : "Cyclodextrin Technology" by József Szejtli, Kluwer Academic Publishers (1988) in the chapter Cyclodextrins in  
15 Pharmaceuticals; "Cyclodextrin Chemistry" by M.L. Bender et al., Springer-Verlag, Berlin (1978); "Advances in Carbohydrate Chemistry", Vol. 12 Ed. by M.L. Wolfrom, Academic Press, New York (1978) in the chapter The Schardinger Dextrins by Dexter French at p. 189-260; "Cyclodextrins and their Inclusions Complexes" by J. Szejtli, Akademiai Kiado, Budapest, Hungary (1982); I. Tabushi in Acc. Chem. Research,  
20 1982, 15, p. 66-72; W. Sanger, Angewandte Chemie, 92, p. 343-361 (1981); A. P. Croft and R. A. Bartsch in Tetrahedron, 39, p. 1417-1474 (1983); Irie et al. Pharmaceutical Research, 5, p. 713-716, (1988); Pitha et al. Int. J. Pharm. 29, 73, (1986); DE 3,118,218; DE-3,317,064; EP-A-94,157; US-4,659,696; and US-4,383,992.

25 Cyclodextrin and the derivatives thereof are known as solubility and/or stability enhancing agents. In particular for the itraconazole compositions of the present invention, the cyclodextrin has a favourable effect on the solubility of the antifungal in the aqueous phase of the composition. Unexpectedly, compositions comprising more  
30 than 10% by weight based on the total weight of the formulation of a cyclodextrin or a derivative thereof were found to exhibit useful mucoadhesive properties.

Hereinafter, the amounts of each of the ingredients in the emulsions are expressed as percentages by weight based on the total weight of the formulation. Similarly, ratios are  
35 intended to define weight-by-weight ratios.

In particular, the concentration of the drug may range from 0.1% to 20%, preferably from 0.5% to 10%, more preferably from 1% to 5% and in particular is 1% to 2%. The amount of cyclodextrin in the present compositions ranges from 10% to about 70%, preferably from 25% to 60% and in particular is 40% to 50%. Generally, the ratio of  
5 the drug, in particular itraconazole, to the cyclodextrin ranges from about 1:700 to 1:2, preferably from 7:120 to 1:10 and in particular is between 1:50 and 1:25.

The emulsions of the present invention consist of an aqueous phase and an oil phase. The compositions may take the form of an oil-in-water (O/W) emulsion, in which the oil  
10 phase is considered to be the internal or dispersed phase while the aqueous phase is considered the external or continuous phase. The subject O/W emulsions have the advantage that the drug, in particular itraconazole, is dissolved in the aqueous, hence external, phase, which is in direct contact with the mucous membranes. The latter will enhance the effectivity of the drug and may lower the required number of applications per  
15 time unit.

Alternatively, the compositions may take the form of a water-in-oil (W/O) emulsion in which the aqueous phase is considered to be the internal or dispersed phase while the oil phase is considered the external or continuous phase. The W/O emulsion has the advantage that it shows favourable spreading properties and optimal mucoadhesive  
20 properties, thus constituting a particularly user-friendly embodiment of the invention. Preferably, the oil phase of the emulsion comprises a mineral oil and more in particular comprises paraffin oil.

The compositions may be applied in the form of conventional products such as creams, capsules, pessaries, gelatin capsules, coated tampons, preparations for the direct  
25 introduction in the vagina by means of cannula supplying devices with manual or mechanic pressure (spray foam) and the like.

In addition to the drug and the cyclodextrin constituents, the subject compositions may further comprise various additives such as emulsifiers, buffer systems, acids or bases,  
30 stabilizing agents, thickening agents, preservatives and the like.

Suitable emulsifiers are, for example, anionic, cationic or, more preferably, nonionic emulsifiers, such as, for example, sucrose esters; glucose esters; polyoxyethylated fatty esters; polyoxyethylated fatty alcohol ethers; glycerol esters, e.g. glycerol monostearate; sorbitan esters, e.g. sorbitan monopalmitate (= Span 40®), sorbitan monostearate  
35 (= Span 60 ®); polyoxyethylene derivatives of sorbitan esters, e.g. polysorbate 40

(= Tween 40®), polysorbate 60 (= Tween 60®), cetyl dimethicon copolyol and the like. Preferably cetyl dimethicon copolyol is used in an amount of 0.5 to 10%, preferably in an amount of approximately 2%.

5 Buffer systems comprise mixtures of appropriate amounts of an acid such as phosphoric, succinic, tartaric, lactic, or citric acid, and a base, in particular sodium hydroxide or disodium hydrogen phosphate. Preferably, said buffer systems maintain the pH of the formulation between 1 and 4, more preferably between 2 and 3. Alternatively, the pH of the composition can be fixed upon addition of an acid such as hydrochloric acid or a base such as sodium hydroxide and the like. The composition of the present invention having  
10 a pH below 3 were well tolerated by the mucous membranes of the vagina. This is clearly unexpected in view of the pH of the art vaginal compositions which are usually only slightly acid (pH of about 4). Further, the low pH of the composition will have a beneficial influence on the anti-microbial effect of the composition.

Suitable stabilizing agents which ensure the physicochemical stability of the composition  
15 are for example inorganic salts, e.g. sodium chloride and the like, 1,2-propanediol, glycerin, and the like. Preferably, sodium chloride and 1,2-propanediol are used in an amount of 0.5 to 5% each, preferably in an amount of approximately 1% sodium chloride and 3% 1,2-propanediol.

The viscosity of the subject formulations may be increased upon the addition of  
20 thickening agents, such as, for example lyophobic agents such as, for example, 1-octadecanol, 1-hexadecanol, glycerol monostearate, Carnuba wax, beeswax, trihydroxystearate and the like; or lyophilic agents such as, for example, cellulose derivatives, e.g. sodium carboxymethylcellulose; polyethylene glycol; chitin and the derivatives thereof, e.g. chitosan; poloxamers; clays; natural gums; starch derivatives;  
25 and the like. Preferably trihydroxystearate is used in an amount of 0.05 to 5%, preferably in an amount of approximately 0.5%.

Preferred compositions are those wherein:

30 the amount of itraconazole is 0.1 to 5%;  
the amount of cyclodextrin is 10 to 70%;  
the amount of thickening agent is 0.05 to 5%;  
the amount of emulsifier is 0.5 to 10%; and  
the amount of stabilizing agent is 0.5 to 10%.

35 More preferred compositions comprise by weight based on the total weight of the composition:

(a) 0.5 to 3% itraconazole;



- (b) 30 to 70% cyclodextrin;
- (c) 0.1 to 1% thickening agent;
- (d) 1 to 5% emulsifier;
- (e) 1 to 4% stabilizing agent;
- 5 (f) buffer, acid or base to maintain the pH of the composition between 1 and 3;
- (g) 0.5 to 50% of a dermatologically acceptable oil; and
- (h) water.

10 A particularly preferred composition comprises approximately by weight based on the total weight of the composition:

- (a) 1 % itraconazole;
- (b) about 43% hydroxypropyl- $\beta$ -cyclodextrin;
- (c) 0.5% trihydroxystearate;
- (d) 2% cetyl dimethicon copolyol;
- 15 (e) 1% sodium chloride and 3% 1,2-propanediol;
- (f) about 0.4% hydrochloric acid and a sufficient amount of sodium hydroxide to maintain the pH of the composition at about pH = 2.7;
- (g) 20% paraffin oil; and
- (h) water.

20

Another particularly preferred composition comprises approximately by weight based on the total weight of the composition :

- (a) 2 % itraconazole;
- (b) about 50% hydroxypropyl- $\beta$ -cyclodextrin;
- 25 (c) 0.5% trihydroxystearate;
- (d) 2% cetyl dimethicon copolyol;
- (e) 1% sodium chloride and 3% 1,2-propanediol;
- (f) about 0.9% hydrochloric acid and a sufficient amount of sodium hydroxide to maintain the pH of the composition at about pH = 2.2;
- 30 (g) 12.5% paraffin oil; and
- (h) water.

To prepare the pharmaceutical compositions of this invention, an effective amount of the drug and the cyclodextrin is combined in intimate admixture with the water and oil phase of the emulsion. In a preferred mode, the preparation of the subject compositions comprises the following steps :

35

- (1) The aqueous phase is prepared containing the drug and the cyclodextrin;

- (2) The acid, base or buffer substances are added to phase (1) until the desired pH is reached;
- (3) The oil phase is prepared upon stirring at a temperature between 80 and 85°C,
- (4) Phase (3) is cooled to below 40°C and the emulsifiers are added;
- 5 (5) Phase (2) and phase (4) are mixed upon stirring.

Optionally, the thus obtained compositions may be homogenized using art-known procedures.

- 10 Optionally, the above procedure is conducted under an inert atmosphere, e.g. nitrogen or oxygen-free argon. It may be advantageous to use micronized forms of the drug. Micronized forms can be prepared by micronization techniques known in the art, e.g. by milling in appropriate mills and sieving through appropriate sieves.
- 15 In a further aspect, the present invention is concerned with the use of the compositions as defined hereinabove for preventing, reducing or curing afflictions of the mucous membranes, in particular of the vagina.  
The present invention is also concerned with a method of preventing, reducing or curing disorders of the mucous membranes and afflictions related thereto, in particular  
20 infections of the vagina, in warm-blooded animals, in particular human beings, which comprises administering vaginally to said warm-blooded animals a composition as defined hereinabove, in an amount effective in preventing, reducing or curing the affliction.
- 25 In general it is contemplated that an effective dosage of the subject compositions would be a treatment of once daily for about 1 to 3 days. It is evident that said effective dosage may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compositions of the instant invention. The effective dosage mentioned hereinabove is therefore a guideline only and  
30 is not intended to limit the scope or use of the invention to any extent.

The following examples are intended to illustrate the scope of the present invention in all its aspects and not to limit it thereto.

35 Example 1: F1 (cream)

Ingredient  
itraconazole

Quantity, mg/g cream  
10

	hydrochloric acid p.a.	4.4
	hydroxypropyl- $\beta$ -CD	436
	1,2-propanediol	30
	sodium hydroxide	q.s. pH = 2.7
5	sodium chloride	10
	paraffin oil	200
	cetyl dimethicon copolyol	20
	trihydroxystearate	5
	purified water	q.s. ad 1g

10

Procedure:

- (1) 10 mg itraconazole and 4.4 mg hydrochloric acid were dissolved in 30 mg 1,2-propanediol upon stirring at 35-40°C;
- (2) 436 mg hydroxypropyl- $\beta$ -CD was dissolved in 284.6 mg purified water upon stirring;
- (3) Then, phase (1) and phase (2) were mixed upon stirring;
- (4) 10 mg of sodium chloride was dissolved in phase (3) upon stirring;
- (5) Concentrated sodium hydroxide was added until pH = 2.7;
- (6) 200 mg paraffin oil and 5 mg trihydroxystearate were mixed upon stirring (25 rpm) at 80-85°C for 30 minutes;
- (7) Phase (6) was cooled upon stirring to below 40°C and 20 mg cetyl dimethicon copolyol was added upon stirring;
- (8) Then, phase (5) and phase (7) were mixed upon stirring for 30 minutes.

25

In a similar way there were prepared :

F2 (cream)

	<u>Ingredient</u>	<u>Quantity, mg/g cream</u>
	itraconazole	20
	hydrochloric acid p.a.	8.9
30	hydroxypropyl- $\beta$ -CD	500
	1,2-propanediol	30
	sodium hydroxide	q.s. pH = 2.2
	sodium chloride	10
	paraffin oil	125
35	cetyl dimethicon copolyol	20
	trihydroxystearate	5
	purified water	q.s. ad 1g

F3 (cream)

	<u>Ingredient</u>	<u>Quantity, mg/g cream</u>
	itraconazole	25
5	hydrochloric acid p.a.	11.1
	hydroxypropyl- $\beta$ -CD	530
	1,2-propanediol	35
	sodium hydroxide	q.s. pH = 2
	paraffin oil	45
10	cetyl dimethicon copolyol	15
	trihydroxystearate	5
	purified water	q.s. ad 1g

15 Example 2

Six female New Zealand White rabbits were administered intravaginally 0.05 g of cream F3 per kg body weight. All animals were examined daily during 4 weeks for clinical signs of waning health, abnormal behaviour or unusual appearance, occurrence of untoward clinical effects and manifestations of irritant, toxic and pharmacological response.

*Conclusions:*

The cream under investigation did not produce an effect on clinical appearance and behaviour. No leakage out of the vagina was seen in any of the test animals during the 4 week period.

25

Example 3

Test solution:

	benzoic acid	2 mg
	hydroxypropyl- $\beta$ -CD	250 mg
30	concentrated HCl	q.s. pH=3.04
	purified water	q.s. ad 1 g

Three female Albino rabbits were administered intravaginally 0.25 g of the test solution per kg body weight during 5 consecutive days. No expulsion of the formulation was seen in any of the test animals during the 5 day period.

35

Claims

1. The use of a cyclodextrin or a derivative thereof as a mucoadhesive in an emulsion or aqueous solution, said cyclodextrin or derivative thereof being used in an amount  
5 from 10% to 70% by weight based on the total weight of the composition.
2. The use according to claim 1 wherein the amount of cyclodextrin ranges from 30% to 60% by weight based on the total weight of the composition.
- 10 3. The use according to claim 1 wherein the composition further comprises a drug.
4. The use according to claim 1 wherein the composition is a vaginal formulation.
5. A mucoadhesive emulsion comprising itraconazole and a cyclodextrin or a derivative thereof in an amount from 10% to 70% by weight based on the total weight of the  
15 composition.
6. A composition according to claim 5 wherein the emulsion is a water-in-oil emulsion.
- 20 7. A composition according to claim 5 wherein the pH is between 1 and 4.
8. A composition according to claim 5 wherein the weight-by-weight ratio of itraconazole to cyclodextrin ranges from 1:700 to 1:2.
- 25 9. A composition according to claim 5 wherein  
the amount of itraconazole is 0.1 to 5%;  
the amount of cyclodextrin is 10 to 70%;  
the amount of thickening agent is 0.05 to 5%;  
the amount of emulsifier is 0.5 to 10%; and  
30 the amount of stabilizing agent is 0.5 to 10%.
10. A process for preparing a composition as claimed in any one of claims 5 to 9  
35 characterized in that a therapeutically effective amount of itraconazole and a cyclodextrin or a derivative thereof are intimately mixed with a water and an oil phase.

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K9/00 A61K47/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,93 15719 (JANSSEN FARMACEUTICI S.P.A.) 19 August 1993 see claims ---	5-10
Y	EP,A,0 579 435 (T.LOFTSSON) 19 January 1994 see claims see page 7, line 8 ---	5-10
Y	EP,A,0 335 545 (UNIVERSITY OF FLORIDA) 4 October 1989 see claims 1,9,17,27,32 see page 121, line 13 - line 33 --- -/--	5-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

30 August 1995

Date of mailing of the international search report

14.09.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Scarponi, U

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 197 571 (JANSSEN PHARMACEUTICA N.V.) 15 October 1986 see claims see page 7, line 26 - line 33 see page 8, line 1 - line 23 ----	5-10
A	CHEMICAL ABSTRACTS, vol. 120, no. 24, 13 June 1994, Columbus, Ohio, US; abstract no. 307253, see abstract & DISS. ABSTR. INT. B, vol.54, no.1, 1993 page 257 H. QI 'INTRAORAL DELIVERY OF CHLORHEXIDINE:COMPLEXATION WITH BETA-CYCLODEXTRIN AND DEVELOPMENT OF BIOADHESIVE FORMULATIONS' -----	1-4
A	US,A,5 055 303 (T.C.RILEY JR.) 8 October 1991 see the whole document -----	1-4

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9315719	19-08-93	AU-B-	661754	03-08-95
		AU-B-	3453593	03-09-93
		CA-A-	2129828	19-08-93
		CN-A-	1076614	29-09-93
		EP-A-	0625899	30-11-94
		JP-T-	7503953	27-04-95
-----				
EP-A-0579435	19-01-94	US-A-	5324718	28-06-94
-----				
EP-A-0335545	04-10-89	US-A-	4983586	08-01-91
		DE-T-	68906942	18-11-93
		ES-T-	2058503	01-11-94
		AU-A-	3176289	27-07-89
		CA-A-	1336498	01-08-95
		IE-B-	62095	14-12-94
		JP-A-	2009825	12-01-90
		US-A-	5017566	21-05-91
		US-A-	5024998	18-06-91
-----				
EP-A-0197571	15-10-86	AT-T-	124055	15-07-95
		AU-B-	583599	04-05-89
		CA-A-	1300130	05-05-92
		DE-D-	3650336	27-07-95
		EP-A-	0636634	01-02-95
		JP-A-	61275301	05-12-86
		US-A-	4870060	26-09-89
		US-A, B	4764604	16-08-88
-----				
US-A-5055303	08-10-91	NONE		
-----				